Indivior posts steep quarterly loss as copycat drugs bite, shares plunge
Share:
(Reuters) - Indivior reported a fourth-quarter loss on Thursday and forecast a further drop in sales this year as the drugmaker grapples with a series of legal defeats related to its top opioid addiction treatment, sending its shares down as much as 22%.The company's Suboxone has been among the main treatments for addiction through a growing epidemic of opioid abuse in the United States. A film variant of Suboxone has lost more than half its market share to cheaper rivals in the last..